United States: Fetal Diagnostics Patent Claims Fall In Inter Partes Review

Post grant inter partes review proceedings have lowered the hurdle to invalidate U.S. patents. The "broadest reasonable construction" of the claims and the lower burden to prove invalidity (by a preponderance of the evidence) of inter partes review proceedings have resulted in many successful challenges. Indeed, the Patent Trial and Appeal Board (PTAB) of the USPTO recently invalidated all challenged claims of a patent claiming methods to diagnose fetal abnormalities. In Ariosa Diagnostics v. The Board of Trustees of the Leland Stanford Junior University (IPR2013-00308) ("Decision") the PTAB invalidated 13 claims of U.S. Patent No. 8,296,076 entitled "Noninvasive Diagnosis of Fetal Aneuoploidy by Sequencing" ("the '076 Patent") assigned to the Board of Trustees of the Leland Stanford Junior University ("Stanford").

The '076 Patent

A chromosomal aneuploidy is a condition where the number of chromosomes in a cell is incorrect, because of either an extra chromosome or a missing chromosome. The discovery of cell-free nucleic acid in the bloodstream of pregnant women has led to the development of non-invasive prenatal tests for a variety of traits. However, the measurement of fetal chromosomal aneuploidy using prenatal diagnostics had remained a challenge because fetal DNA is often less than 10% of the total DNA in maternal cell-free plasma.

The '076 Patent teaches a method to overcome the challenges faced by prior prenatal diagnostics. As noted in the Decision, "[i]n a preferred method of the '076 patent, DNA is obtained from maternal serum, wherein the DNA is mixture of maternal and fetal DNA. The DNA is sequenced partially to provide a large number of short reads, which act as sequence tags with a significant number of the short reads being sufficiently unique such that they can be mapped to specific chromosomes or chromosomal locations of the human genome. By counting the number of sequence tags mapped to each chromosome, the over- and under-representation of any chromosome portion in the mixed DNA contributed by an aneuploidy fetus can be detected.... [t]he method does not rely on a priori sequence information to distinguish fetal DNA from maternal DNA." Decision on page 3, internal citations omitted.

The '076 Patent was filed in the USPTO on April 20, 2012 and claims priority to September 20, 2008. Fifteen claims issued on October 23, 2012. Claim 1 was the only independent claim. Certain key claim elements are bolded.

1. A method of testing for an abnormal distribution of a chromosome in a sample comprising a mixture of maternal and fetal DNA, comprising the steps of:

(a) obtaining maternal and fetal DNA from said sample;

(b) sequencing predefined subsequences of the maternal and fetal DNA to obtain a plurality of sequence tags aligning to the predefined subsequences, wherein said sequence tags are of sufficient length to be assigned to a specific predefined subsequence, wherein the predefined subsequences are from a plurality of different chromosomes, and wherein said plurality of different chromosomes comprise at least one first chromosome suspected of having an abnormal distribution in said sample and at least one second chromosome presumed to be normally distributed in said sample;

(c) assigning the plurality of sequence tags to their corresponding predetermined subsequences;

(d) determining a number of sequence tags aligning to the predetermined subsequences of said first chromosome and a number of sequence tags to the predetermined subsequences of the second chromosome; and

(e) comparing the numbers from step (d) to determine the presence or absence of an abnormal distribution of said first chromosome.

Ariosa's Grounds for Invalidity

Ariosa challenged 13 of the 15 total issued claims of the '076 Patent. Claims 1-5, 7-9, 12 and 13 were alleged to be anticipated under 35 U.S.C. § 102(e) by U.S. Patent Publication No. 2009/0029377, entitled "Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing" filed in the name of inventors Lo et al. ("Lo et al."). Claims 10 and 11 were challenged as being obvious in view of Lo et al. and U.S. Patent Publication No. 2006/0177832. Claims 1-5 and 7-13 were challenged under 35 U.S.C. § 103 for being obvious in view of the combined teachings of U.S. Patent Publication Nos. 2007/0202525 and 2008/0138809. Claim 6 was alleged to be obvious in view of a combination of the above noted patent publications along with Li et al. "Mapping Short DNA Sequencing Reads and Calling Variants Using Mapping Quality Scores. 18 Genome Research 1851-1858 (2008).

Claim Construction of Key Terms

The claims in an inter partes review are interpreted according to their broadest reasonable construction in light of the specification of the patent in which they appear. Decision on page 7. The PTAB broadly construed the claim terms "sequencing predefined subsequences" and "predetermined sequences" which in turn supported a finding of anticipation and obviousness over the cited art.

"sequencing predefined subsequences"

This claim term was construed by the PTAB broadly, therefore including any sequencing method, e.g. shotgun sequencing and hybridization. Stanford argued against this construction, alleging that the methods are limited to targeted sequencing, i.e., only predetermined sequences are actually sequenced. The PTAB disagreed, noting that the term "targeted sequencing" was not recited in the '076 Patent and that the specification disclosed various methods to perform the method steps, including shotgun sequencing. The PTAB also stated that the '076 Patent specification did not limit its teachings to sequencing only the predefined sequences, but rather "discloses sequencing the predefined sequences along with other sequences, and then using various techniques to locate the predefined sequences in the material that has been sequenced." Decision on page 11.

"predetermined subsequences"

The term "predetermined subsequences" was previously construed as "reference sequence information" in the PTAB's decision to grant inter partes review. Decision on page 13. Stanford disagreed, alleging that the term describes "subsequences of said first chromosome" and "subsequences of the second chromosome" and are therefore representative of information that represents less than all of the chromosome. Decision on page 13.

The PTAB found that because step (d) of claim 1 recites "determining a number of sequence tags aligning to the predetermined subsequence of said first chromosome and a number of sequence tags to the predetermined subsequence of the second chromosome", adoption of Stanford's interpretation would read the limitation out of the claim. Thus, the term was construed to be less than the entire chromosome sequence, but two or more predetermined subsequences may include the entire length of the chromosome sequence.


Stanford also requested that the claims of the '076 Patent be construed "as being directed to polymorphism-independent methods of detecting fetal aneuploidy." Decision on page 14. While the patent's specification made repeated reference to the fact that the invention is polymorphism-independent, the PTAB noted that Stanford did not point to any claim language that was consistent with this interpretation. Thus, under the "broadest reasonable construction" standard, the claims were interpreted to encompass methods of testing for both polymorphism-dependent and independent abnormal distributions of a chromosome. Decision on page 15.

Anticipation by Lo et al.

The PTAB interpreted Lo et al. as teaching a method of testing for an abnormal distribution of a fetal chromosome, using genetic material obtained from maternal blood, and those fragments of fetal DNA being sequenced using sequence tags and aligning the tagged sequences to each chromosome. After comparison of the fetal DNA to a reference chromosome, chromosomal gains or losses can be identified. Decision on page 20.

Ariosa contended that with the construction of the claims to include shotgun sequencing, claims 1-5, 7-9, 12 and 13 were anticipated by Lo et al. The PTAB agreed, finding all elements of the construed claims as disclosed in Lo et al. and disagreed with Stanford's argument that the reference did not describe methods using predefined subsequences. Decision on page 23.

Obviousness by Combination of Cited Art

Having determined that most of the claims were anticipated by Lo et al., the PTAB turned to the contentions of obviousness over a combination of references. Interestingly, Stanford presented no evidence or argument to counter Ariosa's allegations that claims 10 and 11 were obvious in view of the combined teachings of Lo et al. and U.S. Patent Publication No. U.S. 2006/0177832. Thus, under a preponderance of the evidence standard, the claims were held as obvious and invalid over the combined teachings of the references.

Claims 1-5 and 7-13 were alleged to be obvious over the combined teachings of U.S. Patent Publication Nos. 2007/0202525 and 2008/0138809. Here, the PTAB agreed with Stanford's defense, i.e., that one of skill in the art would not have combined the references to arrive at the inventions of claim 1-5 and 7-13.

Finally, claim 6 was challenged as allegedly obvious over two alleged combinations of the prior art. The first challenge was over a combination of Lo et al. and Li et al. (Genome Research) and the second over a combination of U.S. Patent Publication Nos: 2007/020525 and 2008/0138809; and Li et al. As no defense was offered by Stanford against the combination of Lo et al. and Li et al., the claim was found invalid as obvious over the combined teachings. For the second challenge, the PTAB found that the combined teachings did not render the claim obvious because it would not be obvious to one of skill in the art to combine the alleged teachings of the cited art.

The Importance of Precise Claiming

The new USPTO inter partes review proceedings provides patent challengers with a cost-effective forum for challenging the validity of any U.S. patent for lack of novelty (35 U.S.C. § 102) or being obvious (35 U.S.C. § 103) in view of printed publications or patent documents. The "preponderance of the evidence" standard is applied in inter partes review, which is a lower burden than the higher "clear and convincing evidence" standard applied in civil actions such as patent infringement cases. Also, and as shown in this decision, the PTAB's construction of patent claims is likely to be broader than in district court, and therefore, the construed claims are more likely to read on prior art. Thus patentees are advised to claim all embodiments of an invention and to clearly articulate an invention's distinctive features in the claims.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.